Literature DB >> 29117486

Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.

Richard M Stone1, Richard A Larson2, Hartmut Döhner3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29117486     DOI： 10.1056/NEJMc1711340

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  New drugs for acute myeloid leukemia inspired by genomics and when to use them.

Authors:  Daniel A Pollyea
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors:  Laura C Michaelis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Treatments targeting MDS genetics: a fool's errand?

Authors:  Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.

Authors:  Montserrat Estruch; Kristian Reckzeh; Camilla Vittori; Anders Centio; Mina Ali; Sophia Engelhard; Ling Zhao; Kyoung Jae Won; Paul Liu; Bo Torben Porse; Kim Theilgaard-Mönch
Journal:  Leukemia       Date:  2020-12-09       Impact factor: 11.528

5.  The growing landscape of FLT3 inhibition in AML.

Authors:  Catherine C Smith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Authors:  Theodore C Tarver; Jason E Hill; Leena Rahmat; Alexander E Perl; Erkut Bahceci; Kenichi Mori; Catherine C Smith
Journal:  Blood Adv       Date:  2020-02-11

7.  A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.

Authors:  Catherine C Smith; Mark J Levis; Olga Frankfurt; John M Pagel; Gail J Roboz; Richard M Stone; Eunice S Wang; Paul L Severson; Brian L West; Mai H Le; Sabine Kayser; Bao Lam; Henry H Hsu; Chao Zhang; Gideon Bollag; Alexander E Perl
Journal:  Blood Adv       Date:  2020-04-28

Review 8.  Genetic and epigenetic determinants of AML pathogenesis.

Authors:  Sheng F Cai; Ross L Levine
Journal:  Semin Hematol       Date:  2018-08-22       Impact factor: 3.851

9.  SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA.

Authors:  Anca Franzini; Anthony D Pomicter; Dongqing Yan; Brayden J Halverson; Orlando Antelope; Clinton C Mason; Jonathan M Ahmann; Anna V Senina; Nadeem A Vellore; Courtney L Jones; Matthew S Zabriskie; Hein Than; Michael J Xiao; Alexandria van Scoyk; Ami B Patel; Phillip M Clair; William L Heaton; Shawn C Owen; Joshua L Andersen; Christina M Egbert; Julie A Reisz; Angelo D'Alessandro; James E Cox; Kevin C Gantz; Hannah M Redwine; Siddharth M Iyer; Jamshid S Khorashad; Nima Rajabi; Christian A Olsen; Thomas O'Hare; Michael W Deininger
Journal:  Blood Cancer Discov       Date:  2019-12-02

10.  Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells.

Authors:  Angel Y F Kam; Sadhna O Piryani; Chang-Lung Lee; David A Rizzieri; Neil L Spector; Stefanie Sarantopoulos; Phuong L Doan
Journal:  Mol Cancer Res       Date:  2021-01-29       Impact factor: 6.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.